Mode
Text Size
Log in / Sign up
Phase 4 Completed N=30 Randomized Triple-blind Treatment

Host Modulatory Effects of β-glucan on Localized Aggressive Periodontitis

Localized Aggressive Periodontitis
Source: ClinicalTrials.gov NCT02402296 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Jun 2015
Primary outcomePrimary: Assessment of Change in Clinical Attachment Level (CAL) — -14.07; -37.48 percentage of change

Summary

combining the non-surgical therapy with a well-tolerated substance that can stimulate protective immune responses like B-glucan, might effectively mount resolution pathways contributing to resolving of the chronic lesion observed in aggressive forms of periodontal disease.

Outcome Measures

OutcomeResultp-value
PRIMARY
Assessment of Change in Clinical Attachment Level (CAL)
-14.07; -37.48
SECONDARY
Pocket Depth (PD)
-21.84; -37.01
SECONDARY
Gingival Index (GI)
-0.87; -75.56
SECONDARY
Matrix Metallo-proteinase (MMP-1&9)
-24.7; -29.5; -21.7; -36.7

Eligibility Criteria

Inclusion Criteria

  • Except for periodontitis, patients were systemically healthy as evaluated by modified Cornell medical index.
  • No more than two teeth other than first molars and incisors, with probing depth (PD) ≥ 5mm, bleeding on probing (BOP), and clinical attachment level (CAL) ≥ 5mm.
  • Rapid rate of attachment loss and bone destruction.
  • A radiographic examination revealing an evidence of moderate to severe vertical bone loss around permanent incisors and first molar teeth.
  • Every patient should have at least 20 teeth excluding third (3rd) molars, and at least an extraction-indicated tooth for a dento-periodontal affection.
  • Familial aggregation.

Exclusion Criteria

  • Previous subgingival scaling and root planing, allergy to β-glucan, smoking, former smoking, pregnancy, need of antibiotic coverage for routine dental therapy, antibiotic therapy in the previous 6 months and allergy to chlorhexidine.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02402296). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search